Patiënten

Patientenzorg

Gezond weefsel beter sparen Dat is het voordeel van protonentherapie.

Bekijk
Waarom protonentherapie Algemene informatie Soorten kanker Ervaringen van patiënten Tips en adviezen Second opinion Jongvolwassen en kanker Lopende studies
Locatie en contactgegevens Wat neemt u mee Vervoer en overnachten Compliment of klacht
Vergoeding van uw behandeling Uw dossier
Research

Research

How HollandPTC works to enhance the benefits of proton therapy

 

View
Our principal investigators Organisations & collaborations Research projects
Pre-clinical and clinical facilities Our research database: how to request data Doing proton research or use our facilities
Practical information on Varian projects R&D communication box Contact
HollandPTC

HollandPTC

Voor de beste protonentherapie van nu en later

Over HollandPTC
Onze visie: Samen beter, beter samen Ons team HollandPTC software
Vrienden van Cliëntenraad Diversiteit en gelijkheid

SAMEN BETER, BETER SAMEN

Patiënten

Patientenzorg

Gezond weefsel beter sparen Dat is het voordeel van protonentherapie.

Bekijk
Over de behandeling Waarom protonentherapie Algemene informatie Soorten kanker Ervaringen van patiënten Tips en adviezen Second opinion Jongvolwassen en kanker Lopende studies
Uw bezoek aan HollandPTC Locatie en contactgegevens Wat neemt u mee Vervoer en overnachten Compliment of klacht
Praktische informatie Vergoeding van uw behandeling Uw dossier
Research

Research

How HollandPTC works to enhance the benefits of proton therapy

 

View
Research at HollandPTC Our principal investigators Organisations & collaborations Research projects
Facilities Pre-clinical and clinical facilities Our research database: how to request data Doing proton research or use our facilities
Practical information Practical information on Varian projects R&D communication box Contact
HollandPTC

HollandPTC

Voor de beste protonentherapie van nu en later

Over HollandPTC
Over HollandPTC Onze visie: Samen beter, beter samen Ons team HollandPTC software
Vrienden van Cliëntenraad Diversiteit en gelijkheid

Proton therapy for ocular melanoma: 3D imaging-driven treatment planning based on patient preferences

Principal Investigator: Prof. dr. Coen Rasch (LUMC)

Funding: KWF 2020

Description

Choroidal melanoma is the most common ocular malignancy in adults, incidence is around 1:100.000 in the Netherlands. Care for this group of patient is centralised, with over 90% of patients being treated at Leiden University Medical Center (LUMC), the remaining patients are mainly treated at Erasmus Medical Center. For small choroidal melanomas (prominence <7mm and largest basal diameter <16mm) Ruthenium-106 plaque brachytherapy is the standard of care, which is only performed at LUMC. Larger choroidal melanomas or those ineligible for brachytherapy (e.g. tumours in close proximity to the optic nerve) were traditionally treated with surgical removal of the eye; enucleation. Eye-preserving treatment by proton therapy (PT) was only available for patients willing and able to go abroad. At EMC, patients could also receive eye-sparing treatment by stereotactic external beam radiotherapy (EBRT) using photons. Since January 2020 PT has become available at the Holland Proton Therapy Center in Delft. Compared to EBRT, PT delivers radiation dose with higher precision, reducing side-effects and undesired dose to the rest of the body. Choroidal melanoma is now a standard indication for PT and is reimbursed for all Dutch patients. Because there is no evidence for PT superiority from randomised controlled trials, Dutch PT centres are obliged to evaluate their outcomes of treatment.

The aim of the project is to determine the outcomes of PT and enucleation for choroidal melanoma in the Netherlands, to better understand patient preferences and treatment decision-making, and to determine whether 3D image-guided proton therapy planning can improve patient-preferred treatment outcomes. The project plan is to:

  • Perform a prospective observational cohort study among 150 patients with large choroidal melanomas will be conducted wherein oncological outcomes, treatment morbidity, visual outcomes and quality of life will be registered up to 36 months after PT or enucleation.
  • Investigate patient treatment preferences and treatment decision-making process regarding the choice between enucleation and PT; to gain insight into patients’ treatment satisfaction, regret and coping with side-effects.
  • Explore the possibilities of the 3D image-guided PT planning to reduce and personalize the risk of side-effects and compare to the current FDA approved software.